Healthcare Apr 30, 2021 04:35 PM (GMT+8) · EqualOcean
Recently, Baiji Shenzhou announced that Btk inhibitor Baiyue Ze ®( A head-to-head global phase III clinical trial comparing with ibotinib in the treatment of adult patients with relapsed or refractory (R / R) chronic lymphoblastic leukemia (CLL) / small lymphocytic lymphoma (SLL) achieved positive results in the mid-term analysis, reaching the primary endpoint of efficacy and the secondary endpoint related to safety. According to the evaluation of the researchers, compared with ibotinib, bayattse was better ® At the same time, the clinical trial reached the safety related pre-set secondary endpoint, and the risk of atrial fibrillation in patients was lower, the difference was statistically significant.
Related companies: